c-erbb-2 antibody (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
c-erbb-2 antibody
C Erbb 2 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c-erbb-2+antibody/c+erbb+2+antibody/pm38909139-36-19-21
Average 90 stars, based on 1 article reviews
C Erbb 2 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c-erbb-2+antibody/c+erbb+2+antibody/pm38909139-36-19-21
Average 90 stars, based on 1 article reviews
c-erbb-2 antibody - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Immunohistochemical staining:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. Staining:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. Modification:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. Amplification:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. Over Expression:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. Expressing:Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of the cell blocks after deparaffinization and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression Article Snippet: Briefly, HER2 immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Article Snippet: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/ neu expression DennisMauricio , Stefania Bellone , LeventMutlu , BlairMcNamara , DiegoD.Manavella , CemDemirkiran , Miguel Skyler Z. Verzosa , Natalia Buza , Pei Hui , Tobias Max Philipp Hartwich , Justin Harold , Yang Yang-Hartwich , Margherita Zipponi , Gary Altwerger , Elena Ratner , Gloria S. Huang , Mitchell Clark , Vaagn Andikyan , Masoud Azodi , Peter E. Schwartz , Alessandro D. Santin a,⁎ Article Title: Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers Article Snippet: Tymon-Rosario et al ., 2021 ( ) , 12 USC cell lines , Article Title: Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression Article Snippet: Briefly, HER2/neu immunohistochemical staining was performed on paraffin-embedded 5 μm sections of cell blocks after deparaffinisation and rehydration, using the Article Title: Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Article Snippet: In the United States, epithelial ovarian (EOC), fallopian tube, and primary peritoneal cancer represent the leading cause of death from gynecologic malignancy.. In 2024, there will be a projected 19,680 new cases and 12,740 resultant deaths in the United States alone [1].. Due in part to a lack of adequate screening tests and non-specific symptoms, over two-thirds of ovarian, fallopian tube, or primary peritoneal cancers are diagnosed at an advanced/metastatic stage (III or IV) [2]. |
